StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) stock

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Provectus Biopharmaceuticals profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Provectus Biopharmaceuticals's profit margin for the twelve months ending Dec 31, 2025 was -1615.8%. For fiscal 2025 it was -1615.8%, against -766.9% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-1615.8%−849.0
FY2024Dec 31, 2024-766.9%−210.7
FY2023Dec 31, 2023-556.2%−196.8
FY2022Dec 31, 2022-359.4%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2025Jun 30, 2025-3156.6%−2824.5
Q1 FY2025Mar 31, 2025-409.2%−197.5
Q4 FY2024Dec 31, 2024-16517.7%−15969.9
Q3 FY2024Sep 30, 2024-924.3%+188.3
Q2 FY2024Jun 30, 2024-332.1%+183.9
Q1 FY2024Mar 31, 2024-211.7%+191.9
Q4 FY2023Dec 31, 2023-547.8%−103.3
Q3 FY2023Sep 30, 2023-1112.6%−886.1
Q2 FY2023Jun 30, 2023-516.0%−180.9
Q1 FY2023Mar 31, 2023-403.6%+145.9
Q4 FY2022Dec 31, 2022-444.5%–
Q3 FY2022Sep 30, 2022-226.5%–
Q2 FY2022Jun 30, 2022-335.0%–
Q1 FY2022Mar 31, 2022-549.5%–

More Provectus Biopharmaceuticals figures

See a number that looks wrong?